Identification of fibrin clot-bound plasma proteins

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Talens, Simone ^a   Leebeek, Frank W G ^a   Demmers, Jeroen A A ^a   Rijken, Dingeman C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA2 MICROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN E; APROTININ; ARGININE CARBOXYPEPTIDASE; BINDING PROTEIN; CALCIUM CHLORIDE; CLUSTERIN; FIBRIN BINDING PROTEIN; FIBRINOGEN; HAPTOGLOBIN; HIGH DENSITY LIPOPROTEIN; PLASMA PROTEIN; PROTEINASE; SERUM AMYLOID P; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; ENZYME INHIBITION; FIBRIN CLOT; HEMOSTASIS; HUMAN; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BLOOD COAGULATION; BLOOD PROTEINS; FIBRIN; HUMANS; MULTIPROTEIN COMPLEXES;

EID: 84864532873     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041966     Document Type: Article

References (45)

1. Prandoni P, (2007) Links between arterial and venous disease. J Intern Med 262: 341-350.
2. Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J, (2008) Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 118: 1659-1667.
3. Holst AG, Jensen G, Prescott E, (2010) Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation 121: 1896-1903.
4. Reiner AP, Siscovick DS, Rosendaal FR, (2001) Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 85: 584-595.
5. White RH, (2003) The epidemiology of venous thromboembolism. Circulation 107: I4-8.
6. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, et al. (2011) Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol 31: 485-493.
7. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ, (2010) Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. Br J Haematol 149: 118-123.
8. Wolberg AS, (2010) Plasma and cellular contributions to fibrin network formation, structure and stability. Haemophilia 16 (Suppl 3): 7-12.
9. Hoylaerts M, Rijken DC, Lijnen HR, Collen D, (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257: 2912-2919.
10. Angles-Cano E, de la Pena Diaz A, Loyau S, (2001) Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 936: 261-275.
11. Nair CH, Dhall DP, (1991) Studies on fibrin network structure: the effect of some plasma proteins. Thromb Res 61: 315-325.
12. Weisel JW, (2007) Structure of fibrin: impact on clot stability. J Thromb Haemost 5 (Suppl 1): 116-124.
13. Koopman J, Haverkate F, Lord ST, Grimbergen J, Mannucci PM, (1992) Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala-Thr. J Clin Invest 90: 238-244.
14. Weisel JW, (2005) Fibrinogen and fibrin. Adv Protein Chem 70: 247-299.
15. Rijken DC, Dirkx SP, Luider TM, Leebeek FW, (2006) Hepatocyte-derived fibrinogen-related protein-1 is associated with the fibrin matrix of a plasma clot. Biochem Biophys Res Commun 350: 191-194.
16. Sahni A, Guo M, Sahni SK, Francis CW, (2004) Interleukin-1beta but not IL-1alpha binds to fibrinogen and fibrin and has enhanced activity in the bound form. Blood 104: 409-414.
17. Iino M, Takeya H, Takemitsu T, Nakagaki T, Gabazza EC, et al. (1995) Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem 232: 90-97.
18. Ohkura N, Enjyoji K, Kamikubo Y, Kato H, (1997) A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin. Blood 90: 1883-1892.
19. Valnickova Z, Enghild JJ, (1998) Human procarboxypeptidase U, or thrombin-activable fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 273: 27220-27224.
20. Mui PT, Ganguly P, (1977) Cross-linking of actin and fibrin by fibrin-stabilizing factor. Am J Physiol 233: H346-349.
21. Huh MM, Schick BP, Schick PK, Colman RW, (1988) Covalent crosslinking of human coagulation factor V by activated factor XIII from guinea pig megakaryocytes and human plasma. Blood 71: 1693-1702.
22. Wilm M, Shevchenko A, Houthaeve T, Breit S, Schweigerer L, et al. (1996) Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry. Nature 379: 466-469.
23. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, et al. (2005) Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4: 1265-1272.
24. Takebe M, Soe G, Kohno I, Sugo T, Matsuda M, (1995) Calcium ion-dependent monoclonal antibody against human fibrinogen: preparation, characterization, and application to fibrinogen purification. Thromb Haemost 73: 662-667.
25. Redgrave TG, Roberts DC, West CE, (1975) Separation of plasma lipoproteins by density-gradient ultracentrifugation. Anal Biochem 65: 42-49.
26. Chu CT, Howard GC, Misra UK, Pizzo SV, (1994) Alpha 2-macroglobulin: a sensor for proteolysis. Ann N Y Acad Sci 737: 291-307.
27. Potempa J, Korzus E, Travis J, (1994) The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 269: 15957-15960.
28. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC, (2006) Proteomic analysis of high-density lipoprotein. Proteomics 6: 721-730.
29. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, et al. (2007) Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 117: 746-756.
30. de Haas CJ, Poppelier MJ, van Kessel KP, van Strijp JA, (2000) Serum amyloid P component prevents high-density lipoprotein-mediated neutralization of lipopolysaccharide. Infect Immun 68: 4954-4960.
31. Henderson RJ, Wasan KM, Leon CG, (2009) Haptoglobin inhibits phospholipid transfer protein activity in hyperlipidemic human plasma. Lipids Health Dis 8: 27.
32. Lee WM, Galbraith RM, (1992) The extracellular actin-scavenger system and actin toxicity. N Engl J Med 326: 1335-1341.
33. Gorg A, Weiss W, Dunn MJ, (2004) Current two-dimensional electrophoresis technology for proteomics. Proteomics 4: 3665-3685.
34. Harpel PC, Hayes MB, Hugli TE, (1979) Heat-induced fragmentation of human alpha 2-macroglobulin. J Biol Chem 254: 8669-8678.
35. Howes JM, Richardson VR, Smith KA, Schroeder V, Somani R, et al. (2012) Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. Diab Vasc Dis Res 9: 216-225.
36. Kunitake ST, Carilli CT, Lau K, Protter AA, Naya-Vigne J, et al. (1994) Identification of proteins associated with apolipoprotein A-I-containing lipoproteins purified by selected-affinity immunosorption. Biochemistry 33: 1988-1993.
37. Park CT, Wright SD, (2000) Fibrinogen is a component of a novel lipoprotein particle: factor H-related protein (FHRP)-associated lipoprotein particle (FALP). Blood 95: 198-204.
38. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, et al. (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24: 2181-2187.
39. Eichinger S, Pecheniuk NM, Hron G, Deguchi H, Schemper M, et al. (2007) High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 115: 1609-1614.
40. Talens S, Hoekstra J, Dirkx SP, Murad SD, Trebicka J, et al. (2011) Proteomic analysis reveals that apolipoprotein A1 levels are decreased in patients with Budd-Chiari syndrome. J Hepatol 54: 908-914.
41. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP, (2008) Multiple actions of high-density lipoprotein. Curr Opin Cardiol 23: 370-378.
42. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, et al. (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57: 392-410.
43. Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernandez JA, (1999) High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 103: 219-227.
44. Oslakovic C, Norstrom E, Dahlback B, (2010) Reevaluation of the role of HDL in the anticoagulant activated protein C system in humans. J Clin Invest 120: 1396-1399.
45. Oslakovic C, Krisinger MJ, Andersson A, Jauhiainen M, Ehnholm C, et al. (2009) Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 284: 5896-5904.